Nuria B. Centeno

Nuria B. Centeno

Auto-generated profile, based on publicly available information

Nuria B. Centeno

Pompeu Fabra University

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMTeresa Mairal
Teresa Mairal
JNJoan Nieto
Joan Nieto
MPMarta Pinto
Marta Pinto
MAMaria Almeida
Maria Almeida
LGLuis Gales
Luis Gales
GVGregorio Valencia
Gregorio Valencia
The thyroid hormone and retinol transporter protein known as transthyretin (TTR) is in the origin of one of the 20 or so known amyloid diseases. TTR self assembles as a homotetramer leaving a central hydrophobic channel with two symmetrical binding sites. The aggregation pathway of TTR into amiloid fibrils is not yet well characterized but in vitro binding of thyroid hormones and other small organic molecules to TTR binding channel results in tetramer stabilization which prevents amyloid formation in an extent which is proportional to the binding constant. Up to now, TTR aggregation inhibitors have been designed looking at various structural features of this binding channel others than its ability to host iodine atoms. In the present work, greatly improved inhibitors have been designed and tested by taking into account that thyroid hormones are unique in human biochemistry owing to the presence of multiple iodine atoms in their molecules which are probed to interact with specific halogen binding domains sitting at the TTR binding channel. The new TTR fibrillogenesis inhibitors are based on the diflunisal core structure because diflunisal is a registered salicylate drug with NSAID activity now undergoing clinical trials for TTR amyloid diseases. Biochemical and biophysical evidence confirms that iodine atoms can be an important design feature in the search for candidate drugs for TTR related amyloidosis.

1 May 2000 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
JLJuan Jose Lozano
Juan Jose Lozano
Manuel PastorManuel Pastor
Manuel Pastor
GCGabriele Cruciani
Gabriele Cruciani
KGKatrin Gaedt
Katrin Gaedt
NCNuria B. Centeno
Nuria B. Centeno
FSFerran Sanz
Ferran Sanz

8 December 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JBJose Brea
Jose Brea
JRJordi Rodrigo
Jordi Rodrigo
Antonio CarrieriAntonio Carrieri
Antonio Carrieri
FSFerran Sanz
Ferran Sanz
MCM. Isabel Cadavid
M. Isabel Cadavid
MLM. Isabel Loza
M. Isabel Loza

7 November 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ECEllen Y. Cotrina
Ellen Y. Cotrina
MPMarta Pinto
Marta Pinto
LBLluís Bosch
Lluís Bosch
MVMarta Vilà
Marta Vilà
DBDaniel Blasi
Daniel Blasi
GVGregorio Valencia
Gregorio Valencia

15 December 2005 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ACAndrea Carotti
Andrea Carotti
MCMaria Isabel Cadavid
Maria Isabel Cadavid
NCNuria B. Centeno
Nuria B. Centeno
CECristina Esteve
Cristina Esteve
MLMaria Isabel Loza
Maria Isabel Loza
BVBernat Vidal
Bernat Vidal

1 July 1997 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
JLJuan Jose Lozano
Juan Jose Lozano
ELE. López-De-Briñas
E. López-De-Briñas
NCN.B. Centeno
N.B. Centeno
RGR. Guigó
R. Guigó
FSFerran Sanz
Ferran Sanz